cover image GLP-1 Pipeline Update: November 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-november-2025 Prime Therapeutics’ GLP-1...

cover image GLP-1 Pipeline Update: Feb 2026 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-february-2026 Prime Therapeutics’ GLP-1...

Cover image for GLP-1 Pipeline Update: February 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-february-2025 Prime Therapeutics’...

Cover image for GLP-1 Pipeline Update: May 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-may-2025 Prime Therapeutics’ GLP-1...

Cover image for GLP-1 Pipeline Update: August 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-august-2025 Prime Therapeutics’ GLP-1...

Cover image Quarterly view of the GLP-1 pipeline and anticipated indications. Prime Therapeutics /glp-1-pipeline-update-november-2024 Prime Therapeutics’ GLP-1 Pipeline Update focuses on the...

GLP-1 pipeline FAQs FDA-approved 2025 2027 Drug name/Manufacturer/Dosage form semaglutide 1.7 mg & 2.4 mg (Wegovy)/Novo Nordisk/SC DISCLAIMER The drug pipeline is fluid; the dates and information...

Drug name/Manufacturer/Dosage form retatrutide/Eli Lilly/SC Drug name/Manufacturer/Dosage form semaglutide (Wegovy)/Novo Nordisk/SC tirzepatide (Zepbound)/Eli Lilly/SC T2DM Access the complete...

Drug name/Manufacturer/Dosage form orforglipron/Eli Lilly/oral retatrutide/Eli Lilly/SC T2DM Diabetic nephropathy (prevention in pts with T2DM & CKD) Alzheimers disease Are generic versions of...

Drug name/Manufacturer/Dosage form semaglutide (Wegovy)/Novo Nordisk/SC - FDA decision 4Q2025 tirzepatide (Zepbound)/Eli Lilly/SC - FDA submission withdrawn Drug name/Manufacturer/Dosage form...

T2DM 2026 Diabetic nephropathy (prevention in pts with T2DM & CKD) T1DM + obesity or overweight Drug name/Manufacturer/Dosage form retatrutide/Eli Lilly/SC Drug name/Manufacturer/Dosage form...

Drug name/Manufacturer/Dosage form retatrutide/Eli Lilly/SC Besides Novo Nordisk and Eli Lilly, what other pharmaceutical companies have GLP1s in the pipeline in late-stage development?...

Maryam Tabatabai, PharmD, vice president of clinical information, and Carole Kerzic, RPh, drug information pharmacist, share more about glucagon-like peptide-1 (GLP-1) receptor agonists in the drug...

Someone holds a GLP-1 pen needle in their hands.

New clinical publication from Prime Therapeutics explores the latest insights for GLP-1s, including trends in spend, drugs in the pipeline, management strategies and more

In the latest episode of the “Pharmacy Friends” podcast, join health outcomes experts for a discussion about Prime’s industry-leading research into persistence and adherence of glucagon-like...

Leading GLP-1 persistence, adherence and clinical outcomes research helps inform health plans and members

Novo Nordisk’s semaglutide (Wegovy) recently received a U.S. Food and Drug Administration (FDA) accelerated approval for treating metabolic dysfunction-associated steatohepatitis (MASH), the first...

Dosage and administration In the VISIONARY trial, sibeprenlimab was administered SC at a dose of 400 mg every 4 weeks and can be self-administered. Place in therapy IgAN, also known as Berger’s...

Submitted supplemental drugs brensocatib oral Manufacturer: PTC Proposed indications Friedreich's ataxia (FA) Clinical overview Mechanism of action Vatiquinone is a first-in-class selective...

New resource page offers the latest GLP-1 insights, research and perspectives

In the latest episode of the “Pharmacy Friends” podcast, hear more from Prime Therapeutics experts about how oral glucagon-like peptide-1 (GLP-1) agonist medications may transform the treatment...

Year 2 Prime Therapeutics’ leading research shows 1 in 12 remain on a GLP-1 drug for obesity at three years. Findings also show improved persistence with high-potency, obesity-approved GLP-1...

Following real-world analysis of GLP-1 drugs for weight loss, Prime/Magellan Rx releases new video about GLP-1 research

New report details the latest on GLP-1s

publications Spring 2025 Prime Therapeutics Report March 21, 2025 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. Our cover story (Page 18)...

Maryam Tabatabai, PharmD, associate vice president of clinical information, offers predictions about forthcoming drug approvals, the latest on a new voucher pilot, updated biosimilar guidance and more

Jessica Johnson, clinical consultant at Prime Therapeutics, shares more about common GLP-1 fraud schemes

GLP-1 year two cost effectiveness study abstract

Real-world study of GLP-1 patients continues to deliver leading insights

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products

Prime's recent analysis shows that patients with obesity stopped using a GLP-1 medication within the first few years of treatment.

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended

publications The evolution of GLP-1s July 31, 2025 Prime's clinical experts share their perspectives on developing a holistic, individualized strategy to capitalize on opportunities and improve...

cover image for the 2025 Spring Prime Therapeutics Report Autoimmune management: Updates and challenges Prime Therapeutics /spring-2025-prime-therapeutics-report The Prime Therapeutics Report is...

Forbes: Injectable glucagon-like peptide-1 agonists, or GLP-1s, were first approved as diabetes medications 20 years ago

David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing...

BioSpace: While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment

Jessica Johnson, clinical consultant at Prime's Special Investigations Unit, shares how to identify fake GLP-1s

Ben Urick, senior director of health outcomes, and Landon Marshall, health outcomes research principal, share more about their educational session and research poster on GLP-1s

In this second of a two-part episode of the Pharmacy Friends podcast, industry experts discuss clinical evidence, drug information and appropriate patient selection for GLP-1 use

Managed Healthcare Executive: A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member,...

Live updates from AMCP Annual Meeting

Event on Sept. 11 in Washington D.C. will feature the latest information on using GLP-1s to tackle the obesity epidemic.

ensitrelvir - Infectious disease Name Manufacturer Clinical use Dosage form Development status - FDA designations FDA decision oxylanthanum carbonate (Renazorb) Unicycive Hyperphosphatemia (in...

Table view Editor-in-chief's message Year 2024 2025 2026 2027 2028 Projected Yearly U.S. Sales $0 $82 $177 $258 $311 The pipeline drug list is an aerial outline of drugs with anticipated FDA...

Reversal in obesity rate syncs with rising usage of expensive GLP-1 medications, but whether the trend will continue in Minnesota is unclear.

Name Manufacturer Clinical use Dosage form Development status - FDA designations FDA decision aflibercept (Eylea HD) 8 mg Regeneron Macular edema from RVO (8 mg dose) Intravitreal sNDA – PR Oct-Dec...

Jessica Johnson, clinical consultant, shares how the Special Investigations Unit at Prime helps identify cases of fraud

Real-world, integrated data follows-up on previous insights, analytics.

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

Lassen, chief clinical officer at Prime Therapeutics/Magellan Rx, shares insights on GLP-1 weight-loss drugs and evidence-based approaches to providing the kind of care we’d want for our loved ones.

Medscape

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more.

The event emphasizes additional measures for obesity therapy.

As demand for GLP-1a drugs for weight loss has increased, new data provides additional insights about this new class of medications.

Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting.

Submitted supplemental drugs Phase 3 supplemental drugs arimoclomol oral Name Manufacturer Clinical Use Dosage Form Development Status camrelizumab Jiangsu Hengrui HCC (unresectable, 1st-line, in...

Drug Generic Name Therapeutic category July2024 Pipeline - Total US sales for 2028 (Dollars in millions) botaretigene sparoparvovec Ophthalmology / Gene therapy $158 crinecerfont Endocrine $325...

Forbes